# Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

> **NCT06305754** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 520 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **BIOLOGICAL:** Sacituzumab tirumotecan
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** H1 Receptor Antagonist
- **DRUG:** H2 Receptor Antagonist
- **DRUG:** Acetaminophen (or equivalent)
- **DRUG:** Dexamethasone (or equivalent)
- **DRUG:** Steroid Mouthwash (dexamethasone or equivalent)

## Key facts

- **NCT ID:** NCT06305754
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-11
- **Primary completion:** 2028-08-17
- **Final completion:** 2030-06-14
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06305754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06305754, "Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06305754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*